GLP-1s Are Going Way Beyond Weight Loss

A quick way to keep the landscape straight is to separate what is approved from what is still being studied. The table below sorts the major conditions into those two buckets.

The Heart Came First

The turning point arrived in March 2024, when the FDA approved a new use for Wegovy — reducing the risk of cardiovascular death, heart attack, and stroke in adults who have heart disease along with overweight or obesity. It was the first time a weight-management drug had been approved specifically to prevent serious heart events.

The decision rested on a large study called SELECT. As the American College of Cardiology summarized, the trial followed 17,604 adults aged 45 and older who had established cardiovascular disease but not diabetes, and found that weekly semaglutide reduced major adverse cardiovascular events — the combined measure doctors call MACE — by about 20 percent compared with placebo over roughly three years. That figure is what moved semaglutide from "helps with weight" into "protects the heart."

Then the Kidneys

Less than a year later, in January 2025, the kidneys joined the list. According to the manufacturer's announcement of the FDA decision, Ozempic became the first GLP-1 medicine approved to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults who have both type 2 diabetes and chronic kidney disease.

Behind that label sat the FLOW trial, which enrolled 3,533 people with diabetes and kidney disease. The results were strong enough that the study was stopped early — a step researchers take only when the benefit is already clear — after a median of about 3.4 years. For a population at high risk of ending up on dialysis, slowing that decline is a meaningful change.

A First-Ever Option for Sleep Apnea

December 2024 brought a genuinely new category. As the American Academy of Sleep Medicine explained, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity — the first time any drug had been approved to treat the condition, which until then was managed mainly with CPAP machines and other devices. In the supporting SURMOUNT-OSA trials, people taking tirzepatide had large drops in the number of breathing interruptions per hour of sleep, and about half no longer met the severity threshold they had entered the study with. For anyone who has struggled to tolerate a CPAP mask, the arrival of a medication option is a notable shift.

And, Most Recently, the Liver

That brings us back to August 2025 and the liver. Per Novo Nordisk's announcement of the U.S. approval, Wegovy received accelerated approval to treat metabolic dysfunction–associated steatohepatitis, or MASH — a condition where fat buildup drives inflammation and scarring (fibrosis) in the liver — in adults with moderate-to-advanced fibrosis who do not yet have cirrhosis. It became the first medication of its kind available for the condition. The approval drew on interim results from the ESSENCE trial, in which a substantially higher share of patients on semaglutide achieved resolution of the liver inflammation without their scarring getting worse, compared with placebo. Because it is an accelerated approval, longer-term confirmatory data are still expected before the benefit is considered fully established.

It is fair to wonder how a single class of medicine can help the heart, kidneys, airway, and liver all at once. The short answer is that GLP-1 is not just an appetite signal. As comprehensive 2025 reviews of these therapies describe, GLP-1 receptors are present in the pancreas, gut, heart, blood vessels, kidneys, and brain — so a drug that activates them is acting in many places, not only in the parts of the brain that govern hunger.

There is a second thread worth knowing about: inflammation. The same body of research suggests these drugs have anti-inflammatory effects, both directly on immune cells and indirectly through better metabolism, and that this calming of inflammation likely contributes to some of the heart and liver benefits seen in trials — not weight loss alone. That distinction matters, because it helps explain why benefits sometimes show up even when weight change does not fully account for them.

Several of the most talked-about uses are still in the research stage, and it is worth being precise about that.

In heart failure with preserved ejection fraction — a hard-to-treat form of heart failure — the STEP-HFpEF program found that semaglutide improved patients' symptoms, physical limitations, and ability to exercise. There is no separate FDA approval for this use yet, but the signal is encouraging. For peripheral artery disease, which causes painful, limited walking, the STRIDE trial reported that a year of semaglutide improved maximum walking distance compared with placebo in people with type 2 diabetes; a U.S. label expansion for that use is under review rather than approved.

Addiction medicine is another frontier. In a 2025 phase 2 trial in JAMA Psychiatry, weekly semaglutide reduced alcohol craving and some measures of drinking over nine weeks — an early, promising result, but not an approved treatment, and one that researchers are still working to confirm in larger studies.

The Alzheimer's Reality Check

The clearest reminder that these drugs are not a cure-all came from neurology. The EVOKE and EVOKE+ trials enrolled roughly 3,808 people with early Alzheimer's disease and tested oral semaglutide against placebo for about two years. They did not show a meaningful benefit on the main measure of cognitive and functional decline, and the company halted its Alzheimer's program as a result. It is exactly the kind of high-profile negative result that tends to get far less coverage than the wins — which is part of why a balanced picture matters.

A few things are worth holding in mind as the news keeps coming. Most of the strongest evidence so far comes from people who have obesity, type 2 diabetes, or established disease — not necessarily from the general population, so the benefits may not translate the same way for everyone.

The side effects are real, too. Reviews of these medicines consistently find that gastrointestinal symptoms are the most common, with nausea affecting up to about half of patients early on, usually easing over time, along with vomiting, diarrhea, and constipation. For some people those effects are the reason they stop taking the drug.

There is also the question of muscle. A 2025 Endocrine Society report found that a meaningful portion of the weight lost on semaglutide can come from lean mass, with older adults and women at higher risk — though the same research suggested that getting enough protein helped people hold on to more muscle. It is a small study and the long-term picture is still developing, but it is a trade-off worth understanding rather than ignoring.

Finally, a note on access. Demand has at times outpaced supply, and the FDA has warned about dosing errors tied to compounded versions of these drugs, which are not reviewed for safety, effectiveness, or quality the way the approved products are.

The bigger story is real: in a remarkably short window, a class of medicines best known for weight loss has become a genuine tool across several major diseases. But "approved for one thing" does not mean "right for you," and the gap between a promising headline and a proven treatment is where careful conversations happen. If any of this feels relevant to your own health, the most useful next step is talking it through with a clinician who knows your history.